Simulations Plus (NASDAQ:SLP) issued its quarterly earnings results on Thursday. The technology company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $0.01, Fidelity Earnings reports. Simulations Plus had a return on equity of 24.57% and a net margin of 25.27%. The business had revenue of $9.40 million for the quarter, compared to the consensus estimate of $8.37 million.
Shares of NASDAQ SLP opened at $34.51 on Friday. The business’s 50-day moving average price is $32.91 and its two-hundred day moving average price is $34.09. Simulations Plus has a one year low of $18.21 and a one year high of $41.95. The company has a market capitalization of $539.30 million, a P/E ratio of 71.90 and a beta of -0.41.
A number of brokerages have recently weighed in on SLP. ValuEngine downgraded Simulations Plus from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Craig Hallum began coverage on Simulations Plus in a research note on Monday. They issued a “buy” rating and a $40.00 target price on the stock. Zacks Investment Research upgraded Simulations Plus from a “hold” rating to a “buy” rating and set a $38.00 target price on the stock in a research note on Wednesday, October 30th. Finally, BidaskClub downgraded Simulations Plus from a “hold” rating to a “sell” rating in a research note on Saturday, January 4th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. Simulations Plus has a consensus rating of “Hold” and a consensus target price of $39.00.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Further Reading: How to Invest in the Dividend Aristocrat Index
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.